Dual antiplatelet therapy after TAVR: A drop in the bucket?

Area of Science:

• Cardiology
• Interventional Cardiology
• Cardiovascular Research

Background:

• Current guidelines suggest 3-6 months of dual antiplatelet therapy (DAPT) post-transcatheter aortic valve replacement (TAVR).
• Oral anticoagulant agents (OAC) are recommended if pre-existing indications exist.
• Recent evidence challenges DAPT's necessity and explores alternatives for TAVR patients.

Purpose of the Study:

• To evaluate the efficacy and safety of aspirin monotherapy versus DAPT after TAVR.
• To explore the potential role of OAC in preventing post-TAVR cerebrovascular events.
• To inform guideline updates regarding antithrombotic therapy following TAVR.

Main Methods:

• Comparative analysis of studies comparing aspirin monotherapy with DAPT.
• Review of data on cerebrovascular events post-TAVR, including causes like atrial fibrillation and subclinical leaflet thrombosis.
• Theoretical consideration of OAC use in specific TAVR patient subgroups.

Main Results:

• Aspirin monotherapy demonstrated comparable efficacy to DAPT with a significant reduction in major bleeding events.
• A substantial proportion of late cerebrovascular events (>24h post-TAVR) may be linked to new-onset atrial fibrillation or subclinical leaflet thrombosis.
• OAC may offer a protective effect against these specific cerebrovascular events compared to antiplatelet therapy.

Conclusions:

• Aspirin monotherapy appears to be a safer alternative to DAPT in many TAVR patients.
• The potential benefit of OAC in preventing specific post-TAVR cerebrovascular events warrants further investigation.
• In the absence of high bleeding risk or recent PCI, OAC could be considered over antiplatelet strategies pending clinical trial results.